相似文献
1
Fluoroquinolone resistance in Campylobacter jejuni isolates in travelers returning to Finland: association of ciprofloxacin resistance to travel destination.
Emerg Infect Dis. 2003 Feb;9(2):267-70. doi: 10.3201/eid0902.020227.
2
Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team.
N Engl J Med. 1999 May 20;340(20):1525-32. doi: 10.1056/NEJM199905203402001.
3
Infection with ciprofloxacin-resistant Campylobacter jejuni in travellers returning from Asia.
Eur J Clin Microbiol Infect Dis. 1996 Apr;15(4):348-50. doi: 10.1007/BF01695672.
4
Campylobacter antimicrobial resistance in Peru: a ten-year observational study.
BMC Infect Dis. 2012 Aug 16;12:193. doi: 10.1186/1471-2334-12-193.
5
High-level quinolone resistance in clinical isolates of Campylobacter jejuni.
J Infect Dis. 1992 Apr;165(4):667-70. doi: 10.1093/infdis/165.4.667.
6
Emergence of fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli in subjects from Finland.
Antimicrob Agents Chemother. 1991 Oct;35(10):2065-9. doi: 10.1128/AAC.35.10.2065.
7
Severe diarrhoea caused by highly ciprofloxacin-susceptible Campylobacter isolates.
Clin Microbiol Infect. 2009 Feb;15(2):188-92. doi: 10.1111/j.1469-0691.2008.02657.x. Epub 2009 Jan 10.
8
Resistance to erythromycin in fluoroquinolone-resistant Campylobacter jejuni strains isolated from human faeces.
J Antimicrob Chemother. 1995 Feb;35(2):351-2. doi: 10.1093/jac/35.2.351.
9
Antimicrobial susceptibilities of Campylobacter strains isolated from Finnish subjects infected domestically or from those infected abroad.
Antimicrob Agents Chemother. 2003 Jan;47(1):102-5. doi: 10.1128/AAC.47.1.102-105.2003.
10
Multidrug resistance in Campylobacter jejuni strains collected from Finnish patients during 1995-2000.
J Antimicrob Chemother. 2003 Dec;52(6):1035-9. doi: 10.1093/jac/dkg489. Epub 2003 Nov 12.
引用本文的文献
1
Role of phage therapy in acute gastroenteritis.
J Res Med Sci. 2025 Jan 30;30:2. doi: 10.4103/jrms.jrms_464_24. eCollection 2025.
2
Consortium of 2029 and 7247 Strains Shows In Vitro Bactericidal Effect on and, in Combination with Prebiotic, Protects Against Intestinal Barrier Dysfunction.
Antibiotics (Basel). 2024 Nov 28;13(12):1143. doi: 10.3390/antibiotics13121143.
3
Reducing antimicrobial use in livestock alone may be not sufficient to reduce antimicrobial resistance among human infections: an ecological study in the Netherlands.
Epidemiol Infect. 2024 Nov 27;152:e148. doi: 10.1017/S0950268824001511.
4
Multidrug-resistant isolated from asymptomatic school-going children in Kibera slum, Kenya.
F1000Res. 2020 Sep 4;9:92. doi: 10.12688/f1000research.21299.2. eCollection 2020.
5
A scoping review of factors associated with antimicrobial-resistant species infections in humans.
Epidemiol Infect. 2023 Jun 7;151:e100. doi: 10.1017/S0950268823000742.
6
Travel-Related Antimicrobial Resistance: A Systematic Review.
Trop Med Infect Dis. 2021 Jan 16;6(1):11. doi: 10.3390/tropicalmed6010011.
7
Emergence of Fluoroquinolone-Resistant and among Australian Chickens in the Absence of Fluoroquinolone Use.
Appl Environ Microbiol. 2020 Apr 1;86(8). doi: 10.1128/AEM.02765-19.
8
Antibiotic therapy in acute gastroenteritis: a single-center retrospective cohort study.
Ann Gastroenterol. 2019 Nov-Dec;32(6):565-569. doi: 10.20524/aog.2019.0422. Epub 2019 Oct 9.
9
Antimicrobial resistance genotypes and phenotypes of Campylobacter jejuni isolated in Italy from humans, birds from wild and urban habitats, and poultry.
PLoS One. 2019 Oct 11;14(10):e0223804. doi: 10.1371/journal.pone.0223804. eCollection 2019.
10
Curcumin Mitigates Immune-Induced Epithelial Barrier Dysfunction by .
Int J Mol Sci. 2019 Sep 28;20(19):4830. doi: 10.3390/ijms20194830.
本文引用的文献
1
Quality control strains used in susceptibility testing of Campylobacter spp.
J Clin Microbiol. 2002 Jul;40(7):2705-6. doi: 10.1128/JCM.40.7.2705-2706.2002.
2
Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia.
Emerg Infect Dis. 2001 Nov-Dec;7(6):996-1003. doi: 10.3201/eid0706.010613.
3
Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates.
Emerg Infect Dis. 2001 Jan-Feb;7(1):24-34. doi: 10.3201/eid0701.010104.
4
Increased resistance to quinolones in Campylobacter jejuni: a genetic analysis of gyrA gene mutations in quinolone-resistant clinical isolates.
Microbiol Immunol. 1998;42(3):223-6. doi: 10.1111/j.1348-0421.1998.tb02274.x.
5
Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years.
Clin Infect Dis. 1998 Feb;26(2):341-5. doi: 10.1086/516303.
6
Evolution of susceptibilities of Campylobacter spp. to quinolones and macrolides.
Antimicrob Agents Chemother. 1994 Sep;38(9):1879-82. doi: 10.1128/AAC.38.9.1879.
7
Susceptibilities to 10 antimicrobial agents of 1,220 Campylobacter strains isolated from 1987 to 1993 from feces of pediatric patients.
Antimicrob Agents Chemother. 1994 Dec;38(12):2917-20. doi: 10.1128/AAC.38.12.2917.
8
Comparative in vitro activities of twelve antimicrobial agents against Campylobacter species.
Antimicrob Agents Chemother. 1985 Mar;27(3):429-30. doi: 10.1128/AAC.27.3.429.
9
Susceptibility of clinical isolates of Campylobacter jejuni to twenty-five antimicrobial agents.
J Antimicrob Chemother. 1986 Dec;18(6):681-5. doi: 10.1093/jac/18.6.681.
Zotero 插件